These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31599747)

  • 1. Mitigating risk of aldosterone in diabetic kidney disease.
    Frimodt-Møller M; Persson F; Rossing P
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):145-151. PubMed ID: 31599747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
    Dojki FK; Bakris G
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):368-374. PubMed ID: 28771453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
    Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
    Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S; López-Mesa M; Gómez-Fernández P
    Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials.
    Albakr RB; Sridhar VS; Cherney DZI
    Am J Kidney Dis; 2023 Dec; 82(6):737-742. PubMed ID: 37517546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?
    Gregg LP; Navaneethan SD
    Nephrol Dial Transplant; 2023 May; 38(6):1355-1365. PubMed ID: 36264349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsteroidal antagonists of the mineralocorticoid receptor.
    Kolkhof P; Nowack C; Eitner F
    Curr Opin Nephrol Hypertens; 2015 Sep; 24(5):417-24. PubMed ID: 26083526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.
    Raj R
    Curr Opin Nephrol Hypertens; 2022 May; 31(3):265-271. PubMed ID: 35165249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease.
    Bayne S; LeFevre J; Olstinske K; Ravindran S; Munusamy S
    Adv Biol (Weinh); 2024 Mar; 8(3):e2300496. PubMed ID: 38065929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.
    Rossing P
    Kidney Int Suppl (2011); 2022 Apr; 12(1):27-35. PubMed ID: 35529090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy.
    Sato A; Nishimoto M
    Hypertens Res; 2022 Aug; 45(8):1310-1321. PubMed ID: 35726084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Hyperkalemia in Heart Failure.
    DeFilippis EM; Desai AS
    Curr Heart Fail Rep; 2017 Aug; 14(4):266-274. PubMed ID: 28656517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
    Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present.
    Epstein M
    Am J Nephrol; 2021; 52(3):209-216. PubMed ID: 33857953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH; Peters CD; Christensen JH; Birn H
    BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
    Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
    Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.
    Cohen S; Sternlicht H; Bakris GL
    Curr Diab Rep; 2022 May; 22(5):213-218. PubMed ID: 35441935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.